Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the developmentand commercialization of targeted immunotherapies for the treatment of cancerand other diseases of the immune system.
Advertisement
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to Favrille's continued listing on, ordelisting from, the Nasdaq Global Market and Favrille's product candidates,proprietary technologies and research and clinical development programs. Suchforward-looking statements involve known and unknown risks, uncertainties andother factors that may cause Favrille's actual results to be materiallydifferent from historical results or from any results expressed or implied bysuch forward-looking statements. These factors include, but are not limitedto, risks and uncertainties related to Favrille's listing status and potentialdelisting of Favrille's common stock from The Nasdaq Global Market, Favrille'sability to continue its operations, conserve cash or recognize value on itsassets and additional risks discussed in Favrille's filings with theSecurities and Exchange Commission. All forward-looking statements arequalified in their entirety by this cautionary statement. Favrille isproviding this information as of the date of this release and, except asrequired by law, does not undertake any obligation to update anyforward-looking statements contained in this release as a result of newinformation, future events or otherwise.
SOURCE Favrille, Inc.
